Transcranial Magnetic Stimulation in Patients with Dual Disorders

Launched by CARDENAL HERRERA UNIVERSITY · Jan 3, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a treatment called transcranial magnetic stimulation (TMS) for patients who have both major depression and tobacco addiction, a situation known as dual disorder. Depression affects millions of people worldwide, and many who struggle with it also find it hard to quit smoking. TMS uses magnetic fields to stimulate brain activity, which may help improve both depression and smoking habits. The study will include 36 adults who have not found relief from traditional medications and will assess their progress at different points during the treatment.

To participate in this trial, individuals must be over 18 years old and have been diagnosed with both major depression and nicotine dependence. They should have not responded well to at least two previous medication treatments. Participants will undergo various evaluations to track their mental health and smoking status before, during, and after the treatment. This study aims to offer a new option for those dealing with these challenging conditions, especially benefiting women who may be disproportionately affected. Remember, the trial is not yet recruiting participants, so there will be more information available soon for those who are interested.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients over 18 years of age being monitored in the mental health area of the province of Castellón, with a dual disorder: major depression and substance abuse disorder
• • Patients who are refractory to two or more lines of pharmacological treatments, ensuring correct completion beforehand
• • Acceptance of informed consent
• Exclusion Criteria:
• • Psychotic symptoms or catatonia
• • Other addictions, or psychiatric or personality disorders
• • Language barrier
• • Mental retardation that will interfere with the ability to understand and subsequent acceptance or rejection of informed consent
• • Patients diagnosed with epilepsy
• • Patients diagnosed with a space-occupying lesion in the brain
• • Tinnitus
• • Confirmed pregnancy; if suspected, a test will be requested
• • Metal piece in the body or implanted medical device, except for dental material